Foxx Development (NASDAQ:FOXX) Releases Earnings Results

20 May 2026, 17:06 by Teresa Graham · The Cerbat Gem

Foxx Development (NASDAQ:FOXX – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($5.19) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $8.67 million during the quarter.

Foxx Development Stock Performance

Shares of FOXX stock traded up $0.09 on Wednesday, hitting $3.94. 13,897 shares of the company’s stock traded hands, compared to its average volume of 13,250. Foxx Development has a one year low of $1.71 and a one year high of $8.88. The company’s fifty day simple moving average is $4.88 and its 200 day simple moving average is $4.53. The stock has a market capitalization of $27.60 million, a price-to-earnings ratio of -1.74 and a beta of -0.10.

Insider Activity at Foxx Development

In related news, CTO James Liao sold 9,716 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $4.61, for a total transaction of $44,790.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 13,766 shares of company stock worth $63,184. 31.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Foxx Development

An institutional investor recently bought a new position in Foxx Development stock. Citadel Advisors LLC acquired a new stake in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,025 shares of the company’s stock, valued at approximately $57,000. Citadel Advisors LLC owned about 0.18% of Foxx Development at the end of the most recent quarter. 60.44% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Foxx Development from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Report on FOXX

Foxx Development Company Profile

(Get Free Report)

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.